替米沙坦治疗慢性阻塞性肺疾病急性加重期并肺动脉高压的疗效观察  

Curative Efficacy of Telmisartan for Pulmonary Hypertension in Patients with COPD in Acute Exacerbation Stage

作　　者：邵发林[1] 

机构地区：[1]甘肃天水市第一人民医院,天水市741000

出　　处：《中国药房》2009年第23期1801-1803,共3页China Pharmacy

摘　　要：目的:观察替米沙坦对慢性阻塞性肺疾病(COPD)急性加重期(AECOPD)并肺动脉高压(PAH)的治疗效应。方法:72例AECOPD并PAH患者分为对照组与治疗组,对照组给予常规治疗,治疗组在常规治疗基础上加用替米沙坦,治疗14d。观察2组治疗前、后肺动脉压力以及胸部X线PAH表现观察指标的变化。结果:治疗组治疗后与其治疗前及与对照组治疗后比较,替米沙坦口服能明显降低肺动脉平均压(mPAP),同时降低胸部X线右下肺动脉干横径、右下肺动脉干横径/气管横径、肺动脉段凸度等肺动脉高压的参数。结论:口服替米沙坦能明显降低AECOPD并PAH。OBJECTIVE： To observe the clinical efficacy of telmisartan for patients with chronic obstructive pulmonary disease （COPD） in acute exacerbation stage （AECOPD）. METHODS： 72 AECOPD cases with pulmonary hypertension （PAH） were divided into control group and treatment group. The control group received routine therapy alone, and the treatment group received Telmisartan additionally for 14 days in addition to the routine therapy. The major outcome measures including the pulmonary artery pressure and the changes of PAH on X ray in the two groups were observed before and after treatment. RESULTS： In the treatment group compared with before treatment within the same group or compared with the control group, oral telmisartan significantly down- regulated mPAP and the PAH parameters on X- ray including right descending pulmonary artery （RDPA）, RDPA/ tracheal transverse diameter, convexity of pulmonary artery etc. CONCLUSION： Telmisartan has remarkable efficacy in decreasing pulmonary hypertension in patients with AECOPD.

关 键 词：替米沙坦 肺动脉高压 慢性阻塞性肺疾病 

分 类 号：R969.4[医药卫生—药理学]